{
  "target_disease": "Obstructive HCM",
  "target_mechanism": "Cardiac myosin inhibitor",
  "last_updated": "2026-02-09",

  "endpoint_registry": {
    "composite_pvo2_nyha": {
      "label": "Composite: pVO2 + NYHA Improvement",
      "category": "composite",
      "display_format": "percentage",
      "sort_order": 1,
      "higher_is_better": true,
      "description": "pVO2 ≥1.5 mL/kg/min increase AND ≥1 NYHA class improvement, OR pVO2 ≥3.0 mL/kg/min increase with no NYHA worsening",
      "endpoint_class": "primary",
      "outcome_type": "clinical",
      "regulatory_precedent": true
    },
    "pvo2_change": {
      "label": "Peak VO2 Change",
      "category": "functional_capacity",
      "display_format": "number",
      "sort_order": 2,
      "higher_is_better": true,
      "description": "Change in peak oxygen consumption from baseline",
      "endpoint_class": "primary",
      "outcome_type": "clinical",
      "regulatory_precedent": true
    },
    "post_exercise_lvot_gradient": {
      "label": "Post-Exercise LVOT Gradient Change",
      "category": "cardiac_function",
      "display_format": "number",
      "sort_order": 3,
      "higher_is_better": false,
      "description": "Change in left ventricular outflow tract gradient after exercise from baseline",
      "endpoint_class": "secondary",
      "outcome_type": "surrogate",
      "regulatory_precedent": true
    },
    "valsalva_lvot_gradient": {
      "label": "Valsalva LVOT Gradient Change",
      "category": "cardiac_function",
      "display_format": "number",
      "sort_order": 4,
      "higher_is_better": false,
      "description": "Change in LVOT gradient during Valsalva maneuver from baseline",
      "endpoint_class": "secondary",
      "outcome_type": "surrogate",
      "regulatory_precedent": true
    },
    "resting_lvot_gradient": {
      "label": "Resting LVOT Gradient",
      "category": "cardiac_function",
      "display_format": "number",
      "sort_order": 5,
      "higher_is_better": false,
      "description": "Resting LVOT gradient absolute value at endpoint",
      "endpoint_class": "secondary",
      "outcome_type": "surrogate",
      "regulatory_precedent": true
    },
    "nyha_improvement": {
      "label": "NYHA Class Improvement ≥1",
      "category": "functional_capacity",
      "display_format": "percentage",
      "sort_order": 6,
      "higher_is_better": true,
      "description": "Proportion of patients achieving ≥1 NYHA functional class improvement",
      "endpoint_class": "secondary",
      "outcome_type": "clinical",
      "regulatory_precedent": true
    },
    "valsalva_lvot_below_30": {
      "label": "Valsalva LVOT-G <30 mmHg",
      "category": "cardiac_function",
      "display_format": "percentage",
      "sort_order": 7,
      "higher_is_better": true,
      "description": "Proportion achieving Valsalva LVOT gradient below 30 mmHg (non-obstructive threshold)",
      "endpoint_class": "secondary",
      "outcome_type": "surrogate",
      "regulatory_precedent": false
    },
    "kccq_os": {
      "label": "KCCQ-OS Change",
      "category": "patient_reported",
      "display_format": "number",
      "sort_order": 8,
      "higher_is_better": true,
      "description": "Kansas City Cardiomyopathy Questionnaire Overall Summary Score change from baseline",
      "endpoint_class": "secondary",
      "outcome_type": "pro",
      "regulatory_precedent": false
    },
    "kccq_css": {
      "label": "KCCQ-CSS Change",
      "category": "patient_reported",
      "display_format": "number",
      "sort_order": 9,
      "higher_is_better": true,
      "description": "Kansas City Cardiomyopathy Questionnaire Clinical Summary Score change from baseline",
      "endpoint_class": "secondary",
      "outcome_type": "pro",
      "regulatory_precedent": false
    }
  },

  "comparators": [
    {
      "id": "mavacamten",
      "drug_name": "CAMZYOS",
      "generic_name": "mavacamten",
      "company": "Bristol-Myers Squibb",
      "ticker": "BMY",
      "mechanism_class": "Cardiac myosin inhibitor (selective, allosteric, reversible)",
      "route": "oral",
      "dosing_summary": "5mg QD starting dose, titrated based on LVEF and Valsalva LVOT gradient",
      "indications": ["Symptomatic NYHA class II-III oHCM"],
      "combination_partners": [],

      "trials": [
        {
          "id": "explorer-hcm",
          "trial_name": "EXPLORER-HCM",
          "nct_id": "NCT03470545",
          "phase": "3",
          "study_design": "rct_double_blind",
          "n_enrolled": 251,
          "n_randomized": 251,
          "duration": "30 weeks",
          "control_arm": "placebo",
          "population_summary": "Symptomatic oHCM, NYHA class II-III, LVOT gradient ≥50 mmHg, LVEF ≥55%, 92% on background beta-blocker or CCB",
          "key_inclusion_criteria": [
            "NYHA class II or III",
            "LVEF ≥55%",
            "Peak LVOT gradient ≥50 mmHg (resting or provoked)",
            "Stable background beta-blocker or calcium channel blocker (or none)"
          ],
          "primary_endpoint_ids": ["composite_pvo2_nyha"],
          "primary_endpoint_strategy": "single",
          "line_of_therapy": "1L",
          "crossover_allowed": false,

          "endpoints": [
            {
              "endpoint_id": "composite_pvo2_nyha",
              "timepoint": "Week 30",
              "value": 37,
              "unit": "%",
              "change_type": "responder_rate",
              "control_value": 17,
              "delta": 19.4,
              "p_value": 0.0005,
              "confidence_interval": [8.7, 30.1],
              "statistical_test": "Cochran-Mantel-Haenszel",
              "multiplicity_adjusted": true,
              "analysis_type": "final",
              "source": "Olivotto I, et al. Lancet 2020;396:759-69",
              "data_maturity": "peer_reviewed"
            },
            {
              "endpoint_id": "post_exercise_lvot_gradient",
              "timepoint": "Week 30",
              "value": -47,
              "unit": "mmHg",
              "change_type": "absolute_change",
              "control_value": -10,
              "delta": -36,
              "assessment_method": "post-exercise",
              "p_value": 0.0001,
              "confidence_interval": [-43.2, -28.1],
              "statistical_test": "ANCOVA",
              "multiplicity_adjusted": true,
              "analysis_type": "final",
              "source": "Olivotto I, et al. Lancet 2020;396:759-69",
              "data_maturity": "peer_reviewed"
            },
            {
              "endpoint_id": "valsalva_lvot_gradient",
              "timepoint": "Week 30",
              "value": -49,
              "unit": "mmHg",
              "change_type": "absolute_change",
              "control_value": -12,
              "delta": -37,
              "assessment_method": "Valsalva",
              "multiplicity_adjusted": false,
              "analysis_type": "final",
              "source": "Olivotto I, et al. Lancet 2020;396:759-69",
              "data_maturity": "peer_reviewed"
            },
            {
              "endpoint_id": "pvo2_change",
              "timepoint": "Week 30",
              "value": 1.4,
              "unit": "mL/kg/min",
              "change_type": "absolute_change",
              "control_value": 0.0,
              "delta": 1.4,
              "p_value": 0.0006,
              "confidence_interval": [0.6, 2.1],
              "statistical_test": "ANCOVA",
              "multiplicity_adjusted": true,
              "analysis_type": "final",
              "source": "Olivotto I, et al. Lancet 2020;396:759-69",
              "data_maturity": "peer_reviewed"
            },
            {
              "endpoint_id": "nyha_improvement",
              "timepoint": "Week 30",
              "value": 65,
              "unit": "%",
              "change_type": "responder_rate",
              "control_value": 31,
              "delta": 34,
              "p_value": 0.0001,
              "confidence_interval": [22.2, 45.4],
              "statistical_test": "Cochran-Mantel-Haenszel",
              "multiplicity_adjusted": true,
              "analysis_type": "final",
              "source": "Olivotto I, et al. Lancet 2020;396:759-69",
              "data_maturity": "peer_reviewed"
            },
            {
              "endpoint_id": "kccq_os",
              "timepoint": "Week 30",
              "value": 14.9,
              "unit": "points",
              "change_type": "absolute_change",
              "control_value": 5.4,
              "delta": 9.1,
              "p_value": 0.0001,
              "confidence_interval": [5.5, 12.8],
              "statistical_test": "MMRM",
              "multiplicity_adjusted": true,
              "analysis_type": "final",
              "source": "Olivotto I, et al. Lancet 2020;396:759-69",
              "data_maturity": "peer_reviewed"
            }
          ],

          "data_events": [
            {
              "event_date": "2020-05-13",
              "event_type": "topline_readout",
              "event_description": "EXPLORER-HCM topline results: primary composite endpoint met with high statistical significance",
              "endpoints_reported": [
                {
                  "endpoint_id": "composite_pvo2_nyha",
                  "timepoint": "Week 30",
                  "value": 37,
                  "unit": "%",
                  "change_type": "responder_rate",
                  "control_value": 17,
                  "delta": 19.4,
                  "p_value": 0.0005,
                  "analysis_type": "final",
                  "source": "MyoKardia press release, May 2020",
                  "data_maturity": "press_release"
                }
              ]
            },
            {
              "event_date": "2020-08-29",
              "event_type": "full_data_presentation",
              "event_description": "EXPLORER-HCM full results presented at ESC 2020 Hot Line Session",
              "endpoints_reported": [
                {
                  "endpoint_id": "composite_pvo2_nyha",
                  "timepoint": "Week 30",
                  "value": 37,
                  "unit": "%",
                  "change_type": "responder_rate",
                  "control_value": 17,
                  "delta": 19.4,
                  "p_value": 0.0005,
                  "statistical_test": "Cochran-Mantel-Haenszel",
                  "multiplicity_adjusted": true,
                  "analysis_type": "final",
                  "source": "ESC 2020 Hot Line Session",
                  "data_maturity": "conference_presentation"
                },
                {
                  "endpoint_id": "post_exercise_lvot_gradient",
                  "timepoint": "Week 30",
                  "value": -47,
                  "unit": "mmHg",
                  "change_type": "absolute_change",
                  "control_value": -10,
                  "delta": -36,
                  "assessment_method": "post-exercise",
                  "p_value": 0.0001,
                  "confidence_interval": [-43.2, -28.1],
                  "multiplicity_adjusted": true,
                  "analysis_type": "final",
                  "source": "ESC 2020 Hot Line Session",
                  "data_maturity": "conference_presentation"
                }
              ]
            },
            {
              "event_date": "2020-09-03",
              "event_type": "publication",
              "event_description": "EXPLORER-HCM primary results published in The Lancet (Olivotto I, et al. Lancet 2020;396:759-69)",
              "endpoints_reported": []
            },
            {
              "event_date": "2021-06-01",
              "event_type": "regulatory_submission",
              "event_description": "NDA submitted to FDA for mavacamten in symptomatic oHCM",
              "endpoints_reported": []
            },
            {
              "event_date": "2022-04-28",
              "event_type": "approval_decision",
              "event_description": "FDA approves CAMZYOS (mavacamten) for treatment of symptomatic NYHA class II-III oHCM",
              "endpoints_reported": []
            }
          ]
        }
      ],

      "safety_profile": {
        "serious_ae_rate": { "pct": 8.0, "n": 10 },
        "ae_categories": [
          {
            "category": "Cardiac",
            "events": [
              {
                "event_name": "LVEF <50%",
                "incidence_pct": 5.7,
                "vs_control_pct": 1.6,
                "is_class_effect": true
              },
              {
                "event_name": "Syncope",
                "incidence_pct": 6.0,
                "vs_control_pct": 2.0,
                "is_class_effect": true
              }
            ]
          },
          {
            "category": "Neurological",
            "events": [
              {
                "event_name": "Dizziness",
                "incidence_pct": 27.0,
                "vs_control_pct": 18.0,
                "is_class_effect": true
              }
            ]
          }
        ],
        "regulatory_warnings": [
          "REMS program (CAMZYOS REMS): echocardiogram before initiation, at weeks 4, 8, 12, and every 12 weeks thereafter",
          "Dose titration based on LVEF and Valsalva LVOT gradient",
          "Contraindicated with strong/moderate CYP2C19 inhibitors",
          "CYP2C19 poor metabolizers: max dose 2.5mg"
        ]
      },

      "regulatory_status": {
        "approval_status": "approved",
        "approved_indications": ["Symptomatic NYHA class II-III oHCM"],
        "label_restrictions": [
          "REMS program (CAMZYOS REMS)",
          "Echo monitoring every 12 weeks",
          "Not recommended if LVEF <55%",
          "CYP2C19 interaction monitoring required"
        ],
        "regulatory_designations": ["breakthrough_therapy", "priority_review"],
        "regulatory_pathway": "priority"
      },

      "commercial": {
        "tam_patients": 280000,
        "pricing_annual_usd": 90000,
        "formulary_status": "restricted",
        "key_commercial_risks": [
          "REMS/echo monitoring burden limits prescriber adoption",
          "Aficamten competition with second-in-class entry",
          "CYP2C19 drug-drug interactions limit eligible patients"
        ]
      }
    },

    {
      "id": "aficamten",
      "drug_name": "Myqorzo",
      "generic_name": "aficamten",
      "company": "Cytokinetics",
      "ticker": "CYTK",
      "mechanism_class": "Cardiac myosin inhibitor (selective, allosteric, reversible)",
      "route": "oral",
      "dosing_summary": "5mg starting dose, titrated in 5mg increments to max 20mg",
      "indications": ["Symptomatic oHCM to improve functional capacity and symptoms"],
      "combination_partners": [],

      "trials": [
        {
          "id": "sequoia-hcm",
          "trial_name": "SEQUOIA-HCM",
          "nct_id": "NCT05186818",
          "phase": "3",
          "study_design": "rct_double_blind",
          "n_enrolled": 282,
          "n_randomized": 282,
          "duration": "24 weeks",
          "control_arm": "placebo",
          "population_summary": "Symptomatic oHCM, NYHA class II-III, LVEF ≥60%, resting LVOT-G ≥30 mmHg, post-Valsalva LVOT-G ≥50 mmHg; 101 sites in 14 countries; 61.3% on beta-blockers, 28.7% on CCBs, 12.8% on disopyramide",
          "key_inclusion_criteria": [
            "NYHA class II or III",
            "LVEF ≥60%",
            "Resting LVOT gradient ≥30 mmHg",
            "Post-Valsalva LVOT gradient ≥50 mmHg"
          ],
          "primary_endpoint_ids": ["pvo2_change"],
          "primary_endpoint_strategy": "single",
          "line_of_therapy": "1L",
          "crossover_allowed": false,

          "endpoints": [
            {
              "endpoint_id": "pvo2_change",
              "timepoint": "Week 24",
              "value": 1.8,
              "unit": "mL/kg/min",
              "change_type": "absolute_change",
              "control_value": 0.0,
              "delta": 1.74,
              "p_value": 0.000002,
              "confidence_interval": [1.04, 2.44],
              "statistical_test": "ANCOVA",
              "multiplicity_adjusted": true,
              "analysis_type": "final",
              "source": "Maron MS, et al. N Engl J Med 2024",
              "data_maturity": "peer_reviewed"
            },
            {
              "endpoint_id": "kccq_css",
              "timepoint": "Week 24",
              "value": 12,
              "unit": "points",
              "change_type": "absolute_change",
              "control_value": 5,
              "delta": 7,
              "p_value": 0.0001,
              "confidence_interval": [5, 10],
              "statistical_test": "MMRM",
              "multiplicity_adjusted": true,
              "analysis_type": "final",
              "source": "Maron MS, et al. N Engl J Med 2024",
              "data_maturity": "peer_reviewed"
            },
            {
              "endpoint_id": "nyha_improvement",
              "timepoint": "Week 24",
              "value": 58.5,
              "unit": "%",
              "change_type": "responder_rate",
              "control_value": 24.3,
              "delta": 34.2,
              "p_value": 0.0001,
              "statistical_test": "logistic regression",
              "multiplicity_adjusted": true,
              "analysis_type": "final",
              "source": "Maron MS, et al. N Engl J Med 2024",
              "data_maturity": "peer_reviewed"
            },
            {
              "endpoint_id": "valsalva_lvot_gradient",
              "timepoint": "Week 24",
              "value": -47.6,
              "unit": "mmHg",
              "change_type": "absolute_change",
              "control_value": 1.8,
              "delta": -50,
              "assessment_method": "Valsalva",
              "p_value": 0.0001,
              "confidence_interval": [-57, -44],
              "statistical_test": "ANCOVA",
              "multiplicity_adjusted": true,
              "analysis_type": "final",
              "source": "Maron MS, et al. N Engl J Med 2024",
              "data_maturity": "peer_reviewed"
            },
            {
              "endpoint_id": "valsalva_lvot_below_30",
              "timepoint": "Week 24",
              "value": 49.3,
              "unit": "%",
              "change_type": "responder_rate",
              "control_value": 3.6,
              "delta": 45.7,
              "assessment_method": "Valsalva",
              "p_value": 0.0001,
              "multiplicity_adjusted": true,
              "analysis_type": "final",
              "source": "Maron MS, et al. N Engl J Med 2024",
              "data_maturity": "peer_reviewed"
            },
            {
              "endpoint_id": "resting_lvot_gradient",
              "timepoint": "Week 24",
              "value": 20,
              "unit": "mmHg",
              "change_type": "raw_value",
              "control_value": 60,
              "delta": -40,
              "assessment_method": "resting",
              "p_value": 0.0001,
              "multiplicity_adjusted": true,
              "analysis_type": "final",
              "source": "Maron MS, et al. N Engl J Med 2024",
              "data_maturity": "peer_reviewed"
            }
          ],

          "data_events": [
            {
              "event_date": "2024-01-09",
              "event_type": "topline_readout",
              "event_description": "SEQUOIA-HCM topline results: met primary endpoint and all 10 hierarchically tested secondary endpoints",
              "endpoints_reported": [
                {
                  "endpoint_id": "pvo2_change",
                  "timepoint": "Week 24",
                  "value": 1.8,
                  "unit": "mL/kg/min",
                  "change_type": "absolute_change",
                  "control_value": 0.0,
                  "delta": 1.74,
                  "p_value": 0.000002,
                  "analysis_type": "final",
                  "source": "Cytokinetics press release, January 2024",
                  "data_maturity": "press_release"
                }
              ]
            },
            {
              "event_date": "2024-05-12",
              "event_type": "full_data_presentation",
              "event_description": "SEQUOIA-HCM full results presented at Heart Failure Association of the ESC (ESC-HF 2024)",
              "endpoints_reported": [
                {
                  "endpoint_id": "pvo2_change",
                  "timepoint": "Week 24",
                  "value": 1.8,
                  "unit": "mL/kg/min",
                  "change_type": "absolute_change",
                  "control_value": 0.0,
                  "delta": 1.74,
                  "p_value": 0.000002,
                  "confidence_interval": [1.04, 2.44],
                  "statistical_test": "ANCOVA",
                  "multiplicity_adjusted": true,
                  "analysis_type": "final",
                  "source": "ESC-HF 2024 Late-Breaking Clinical Trials",
                  "data_maturity": "conference_presentation"
                },
                {
                  "endpoint_id": "nyha_improvement",
                  "timepoint": "Week 24",
                  "value": 58.5,
                  "unit": "%",
                  "change_type": "responder_rate",
                  "control_value": 24.3,
                  "delta": 34.2,
                  "p_value": 0.0001,
                  "multiplicity_adjusted": true,
                  "analysis_type": "final",
                  "source": "ESC-HF 2024 Late-Breaking Clinical Trials",
                  "data_maturity": "conference_presentation"
                }
              ]
            },
            {
              "event_date": "2024-05-24",
              "event_type": "publication",
              "event_description": "SEQUOIA-HCM results published in New England Journal of Medicine (Maron MS, et al.)",
              "endpoints_reported": []
            },
            {
              "event_date": "2025-02-15",
              "event_type": "regulatory_submission",
              "event_description": "NDA submitted to FDA for aficamten in symptomatic oHCM",
              "endpoints_reported": []
            },
            {
              "event_date": "2025-12-19",
              "event_type": "approval_decision",
              "event_description": "FDA approves Myqorzo (aficamten) for symptomatic oHCM",
              "endpoints_reported": []
            }
          ]
        }
      ],

      "safety_profile": {
        "serious_ae_rate": { "pct": 5.6, "n": 8 },
        "dose_reduction_rate": { "pct": 4.9, "n": 7 },
        "ae_categories": [
          {
            "category": "Cardiac",
            "events": [
              {
                "event_name": "LVEF <50%",
                "incidence_pct": 3.5,
                "vs_control_pct": 0.7,
                "is_class_effect": true
              },
              {
                "event_name": "Palpitations",
                "incidence_pct": 7.0,
                "vs_control_pct": 2.9,
                "is_class_effect": false
              },
              {
                "event_name": "Atrial fibrillation",
                "incidence_pct": 2.8,
                "vs_control_pct": 2.9,
                "is_class_effect": false
              }
            ]
          },
          {
            "category": "Vascular",
            "events": [
              {
                "event_name": "Hypertension",
                "incidence_pct": 7.7,
                "vs_control_pct": 2.1,
                "is_class_effect": false
              }
            ]
          }
        ],
        "regulatory_warnings": [
          "REMS program (Myqorzo REMS)",
          "Boxed warning: risk of heart failure due to systolic dysfunction",
          "Echo monitoring required before and during treatment",
          "Not recommended if LVEF <55%"
        ]
      },

      "regulatory_status": {
        "approval_status": "approved",
        "approved_indications": ["Symptomatic oHCM to improve functional capacity and symptoms"],
        "label_restrictions": [
          "REMS program (Myqorzo REMS)",
          "Boxed warning: risk of heart failure due to systolic dysfunction",
          "Echo monitoring required",
          "Not recommended if LVEF <55%"
        ],
        "regulatory_designations": ["breakthrough_therapy"],
        "regulatory_pathway": "standard"
      },

      "commercial": {
        "tam_patients": 280000,
        "launch_date": "2026-01-20",
        "formulary_status": "restricted",
        "key_commercial_risks": [
          "Mavacamten established first-mover advantage with 3+ years on market",
          "REMS program required (contrary to initial market expectations)",
          "Pricing pressure from mavacamten competition"
        ]
      }
    }
  ],

  "cross_trial_caveats": [
    "Different primary endpoints: EXPLORER-HCM used a composite (pVO2 + NYHA improvement), SEQUOIA-HCM used pVO2 change alone — not directly comparable",
    "Different trial durations: 30 weeks (EXPLORER) vs 24 weeks (SEQUOIA)",
    "Different baseline LVEF entry criteria: ≥55% (EXPLORER) vs ≥60% (SEQUOIA)",
    "Different background therapy rates and types across trial populations",
    "No head-to-head trial data available between mavacamten and aficamten"
  ],

  "key_debates": [
    {
      "question": "Is aficamten's LVEF <50% rate (3.5%) meaningfully better than mavacamten's (5.7%), given both now require REMS?",
      "bull_view": "Lower LVEF signal + shorter half-life = faster dose optimization and recovery from over-inhibition. 3.5% vs 5.7% is a ~40% relative reduction in the key safety event.",
      "bear_view": "Both drugs require REMS and echo monitoring. The absolute difference (2.2 percentage points) is small and may not change prescribing behavior. Real-world data needed.",
      "resolution_catalyst": "Real-world comparative safety data and FOREST-HCM long-term extension results"
    },
    {
      "question": "Can aficamten differentiate on monitoring burden and drug interactions given both drugs now require REMS?",
      "bull_view": "Aficamten avoids CYP2C19 DDI issues that limit mavacamten in ~15% of patients on common co-medications. Simpler titration with shorter half-life.",
      "bear_view": "CAMZYOS has 3+ years of real-world safety data and established payer/prescriber relationships. REMS parity neutralizes aficamten's pre-launch narrative advantage.",
      "resolution_catalyst": "Formulary decisions, payer coverage terms, and real-world prescribing patterns in first 12 months post-launch"
    },
    {
      "question": "Does aficamten's shorter half-life (~2 weeks to steady state vs 4-6 weeks for mavacamten) translate to meaningful clinical advantage?",
      "bull_view": "Faster titration enables quicker symptom relief and dose optimization. Faster washout in safety events — LVEF recovers in days vs weeks.",
      "bear_view": "Most patients are titrated at quarterly visits regardless. The PK advantage is theoretical until real-world evidence demonstrates better outcomes.",
      "resolution_catalyst": "MAPLE-HCM (aficamten vs metoprolol) data and real-world clinical experience"
    }
  ]
}
